<DOC>
	<DOCNO>NCT02617667</DOCNO>
	<brief_summary>The objective study compare safety , efficacy , tolerability two different dose level CyclASol Ophthalmic Solutions placebo ( vehicle ) Restasis treatment sign symptom Dry Eye Disease ( DED ) .</brief_summary>
	<brief_title>CyclASol Treatment Moderate Severe Dry-eye Disease ( DED )</brief_title>
	<detailed_description>This phase 2 study explore safety , efficacy tolerability two CyclASol concentration one drop twice daily versus vehicle ( placebo ) . In addition mask vehicle control arm , open-label comparator arm consist Restasis include . The study explore range sign symptom DED gain understand possible treatment effect comparison vehicle estimation effect size . In line current treatment guideline , propose phase 2 population consist patient suffer moderate severe DED .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Signed Informed Consent Form HIPAA ( Health Insurance Portability Accountability Act ) document Patientreported history dry eye eye Current use overthecounter and/or prescription eye drop dry eye symptom Ability willingness follow instruction , include participation study assessment visit Women pregnant , nurse plan pregnancy Unwillingness submit blood pregnancy test screen last visit ( early termination visit ) childbearing potential , unwillingness use acceptable mean birth control Clinically significant slitlamp finding abnormal lid anatomy screen DED secondary scar ocular periocular malignancy History herpetic keratitis Active ocular allergy ocular allergy expect active study period Ongoing ocular systemic infection screen baseline Wear contact lenses within 3 month prior screen anticipate use contact lenses study History response previous topical Cyclosporine A and/or use topical Cyclosporine A within 6 month prior screen Intraocular surgery ocular laser surgery within previous 6 month , plan ocular and/or lid surgery study period Presence uncontrolled systemic disease Presence know allergy and/or sensitivity study drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>